Answers are grounded in this paper and cite their sources.
In a large cohort of patients with advanced CUP-NETs treated with PRRT in a real-world scenario and followed up to 14 years after the commencement, PRRT has demonstrated favorable and clinically significant efficacy and survival with minimal and acceptable side effects. Our results indicate that PRRT is a well-tolerated and effective treatment option for patients with metastatic CUP-NETs expressing somatostatin receptors.
No takes yet. Share an insight, caveat, or question.
Baum et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: